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a b s t r a c t
The highly conserved internal nucleoprotein (NP) is a promising antigen to develop a universal inﬂuenza
A virus vaccine. In this study, mice were injected intramuscularly with Escherichia coli-derived NP
protein alone or in combination with adjuvant alum (Al(OH)3), CpG or both. The results showed that the
NP protein formulated with adjuvant was effective in inducing a protective immune response.
Additionally, the adjuvant efﬁcacy of Al(OH)3 was stronger than that of CpG. Optimal immune responses
were observed in BALB/c mice immunized with a combination of NP protein plus Al(OH)3 and CpG. These
mice also showed maximal resistance following challenge with inﬂuenza A virus PR8 strain. Most
importantly, 10 mg NP formulated with Al(OH)3 and CpG induced higher protection than did 90 mg NP.
These ﬁndings indicated that a combination of Al(OH)3 and CpG may be an efﬁcient adjuvant in the NP
formulation.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Seasonal inﬂuenza epidemics and the inevitable delay between
viral identiﬁcation and production of the speciﬁc vaccine have high-
lighted the urgent need for next-generation inﬂuenza vaccines that
can preemptively induce broad immunity to different viral strains.
Inﬂuenza (ﬂu) is a serious hazard to human health, and vaccination is
the most effective method for preventing ﬂu. However, the conven-
tional ﬂu vaccine is produced in special-pathogen-free (SPF) chicken
eggs, and it takes 4–6 months to obtain subtype-matched vaccine
from the vaccine strain. Moreover, conventional ﬂu vaccines induce
protective effects depending on antibodies against highly variable
hemagglutinin (HA) and neuraminidase (NA) (Gerdil, 2003). In most
cases, it is difﬁcult to prevent ﬂu epidemics or pandemics caused by a
new type of inﬂuenza A virus (Fedson, 2005; Palese, 2006). Therefore,
universal ﬂu vaccines based on conserved inﬂuenza A virus antigens
are required to prevent ﬂu outbreaks.
Nucleoprotein (NP) is a highly conserved internal antigen of the
inﬂuenza A virus (Altmuller et al., 1989; Shu et al., 1993) and is the
major target antigen for cytotoxic T lymphocyte (CTL) responses
(Jameson et al., 1998, 1999; McMichael et al., 1983, 1986). At this
time, several vaccines based on the NP antigen alone or in
combination with other inﬂuenza A virus antigens have been
developed including peptide vaccines (Adar et al., 2009; Atsmon
et al., 2012; Gao et al., 2013; Jeon et al., 2002; Savard et al., 2012),
DNA-based vaccines (Kheiri et al., 2012; Lalor et al., 2008; Luo et
al., 2012; Price et al., 2009, 2010; Xu et al., 2011), virus vector-
based vaccines (Price et al., 2009, 2010; Antrobus et al., 2012, 2014;
Barefoot et al., 2009; Berthoud et al., 2011; Brewoo et al., 2013;
Hessel et al., 2014; Kim et al., 2013; Lambe et al., 2013; Li et al.,
2013; Lillie et al., 2012; Moraes et al., 2011; Mullarkey et al., 2013;
Rohde et al., 2013; Sipo et al., 2011; Vitelli et al., 2013), recombi-
nant attenuated Salmonella vaccines (RASVs) (Ashraf et al., 2011)
or protein subunit vaccines (Luo et al., 2012; Haynes et al., 2012;
MacLeod et al., 2013). The efﬁcacy of these vaccines has been
evaluated in animal models. Numerous studies have found that
NP-based protein subunit vaccines can protect animals against
homologous and heterologous inﬂuenza virus. As early as 1986,
Wraith et al. (1987) puriﬁed NP of inﬂuenza A virus X31 (H3N2)
and injected BALB/c mice with two 10-mg doses of NP s.c. at 4-
week intervals or with one 50-mg dose i.p. They found that NP
immunization resulted in signiﬁcant protection (75%) of mice from
a lethal challenge with PR8. However, the protective efﬁcacy of NP
protein-based vaccines requires improvement, possibly using an
adjuvant. Next, Tamura et al. (1996) expressed rNP of PR8 in insect
cells and found that intranasal immunization of mice with 5 mg
rNP combined with the adjuvant cholera toxin B subunit (CTB)
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could accelerate viral clearance from the nasal site after a sublethal
dose challenge of inﬂuenza virus. Moreover, rNP combined with
CTB could protect 70–80% of mice against homologous challenge
with PR8 (40LD50) and 40–70% of mice against heterologous
challenge with B/Ibaraki/2/85 (B/Ibaraki) (40LD50). Later, Guo
et al. (2010) used CTB in the formulation of rNP and found that
intranasal immunization of mice with 10 mg rNP with CTB resulted
in complete protection against the homologous inﬂuenza virus
(10LD50), and immunization with 100 mg rNP with CTB provided
good cross-protection against heterologous H5N1 and H9N2 avian
inﬂuenza viruses (5LD50). MacLeod et al., (2013) found that NP
delivered with adjuvant aluminum completely protected mice
against homologous challenge with PR8. In contrast, immunization
with NP delivered with alum and the detoxiﬁed LPS adjuvant
monophosphoryl lipid A (MPL) provided some protection against
the homologous viral strain but no protection against infection by
inﬂuenza expressing a variant NP. Together, these data suggest that
the NP protein subunit vaccine is immunogenic in mice and could
provide protection against homologous and heterologous inﬂu-
enza viral challenge in the appropriate formulation.
Protein subunits are preferred in vaccine research because of
their increased safety, single antigenic component, coverage of
more antigen epitopes, and suitability for large-scale production.
In our previous studies, the codon-optimized NP protein of the
inﬂuenza virus A/Beijing/30/95 (H3N2) was expressed in Escher-
ichia coli at high levels and administered at a high dose, and it was
found to induce protection with high efﬁciency (Huang et al.,
2012). In most cases, protein-based vaccines are poor immunogens
and require the addition of adjuvants in the formulation to induce
a protective and long-lasting immune response, even though they
are advantageous over traditional vaccines considering safety and
production cost. Insoluble aluminum salt is a universally used and
safe adjuvant (Reed et al., 2009), and CpG is under development as
an adjuvant for vaccines against cancer and infectious diseases
(Cooper et al., 2004; Gupta and Cooper, 2008). In this study,
aluminum and CpG were used to improve the immunogenicity of
NP protein derived from E. coli. We investigated whether 10 mg NP
in combination with adjuvant alum and CpG provides comparable
cross protection as 90 mg NP without adjuvant in mice (Fig. 1).
Results
Adjuvant Al(OH)3 and CpG signiﬁcantly increased the humoral
immune response induced by inﬂuenza A virus NP subunit vaccine
We explored whether adjuvant Al(OH)3 and CpG increased the
immune response elicited by NP protein (Fig. 2). We found that
priming vaccination with NP alone or combined with adjuvant
induced substantial anti-NP IgG (1.8104–3.2104), and the IgG
titers were not signiﬁcantly different from each other in the NP-
immunized groups.
Boosting immunization performed on day 14 improved anti-NP
IgG titers; an NP-speciﬁc IgG assay performed on day 28 (Fig. 2,
middle) showed that 10 mg NP alone induced higher anti-NP IgG
levels (geometric mean: 6.8105). The addition of CpG (G4)
induced signiﬁcantly higher anti-NP IgG titers (geometric mean:
1.8106) than did 10 mg NP alone (G3) (G44G3, po0.01), and the
addition of Al(OH)3 (G5) induced similar anti-NP IgG titers (geo-
metric mean: 2.8106) as did G4 (G5EG4, p40.05). Adding
Al(OH)3 plus CpG and 10 mg NP (G6) induced higher anti-NP IgG
titers (geometric mean: 4.0106) than did G4 alone (G64G4,
po0.05). However, the anti-NP IgG titers in G5 and G6 were
similar (p40.05). Immunization with 90 mg NP (G7) induced
similar anti-NP IgG titers (geometric mean: 1.1106) as did G3
and G4 (G7EG3 and G4, p40.05), but lower titers compared with
G5 and G6 (G7oG5 and G6, po0.001).
After the third immunization, anti-NP IgG titers did not
improve in mice immunized with 10 mg NP protein alone (G3),
NP protein formulated with CpG (G4) or NP protein formulated
with Al(OH)3 and CpG together (G6), compared with after the
second immunization. However, anti-NP IgG titers in G5 (po0.05)
and G7 (po0.05) improved signiﬁcantly. As a result, after the third
immunization, mice in G5, G6, and G7 showed comparable anti-NP
IgG titers (G5EG6EG7, p40.05), which were signiﬁcantly higher
than that in G3 (G5, G6 and G74G3, po0.001). The anti-NP IgG
titer in G4 was signiﬁcantly higher than that in G3 (G44G3,
po0.01), comparable to that in G7 (G4EG7, p40.05) and
signiﬁcantly lower than those in G5 and G6 (G4oG5 and G6,
po0.001).
Antibody subtype analysis (Fig. 3) showed that CpG signiﬁcantly
improved anti-NP IgG2a titer (G44G3 and G7, po0.01), but not anti-
NP IgG1 titer (p40.05), compared with immunization with NP alone
(G3 and G7) (Fig. 3A and B). This decreased the anti-NP IgG1/IgG2a
ratio (Fig. 3C), indicative of a potent Th1 response. Al(OH)3 adjuvant
signiﬁcantly increased both anti-NP IgG1 (G54G4, po0.001) and
IgG2a (G54G4, po0.05) titers compared with CpG (Fig. 3A, B),
resulting in the highest IgG1/IgG2a ratio (Fig. 3C), which differed from
the IgG1/IgG2a pattern in G4 (G54G4, po0.001). In G6, lower anti-
NP IgG1 (G6oG5, po0.01) and similar IgG2a (G6EG5, p40.05)
titers were induced, resulting in a lower IgG1/IgG2a ratio compared
with group 5 (G6oG5, po0.01) (Fig. 3C). These results suggest that Al
(OH)3 improved the Th2 antibody response against NP protein, which
may have beenweakened by including CpG in G6. Slightly higher anti-
NP IgG1 (G74G3, po0.05) and similar IgG2a (G7EG3, p40.05)
levels were induced in G7 compared with G3, resulting in a similar
IgG1/IgG2a ratio of these two groups (G7EG3, p40.05) (Fig. 3).
Adjuvant CpG or Al(OH)3 plus CpG improved the cellular immune
response induced by inﬂuenza A virus NP subunit vaccine
To characterize the cellular immune responses elicited by NP
protein in mice, IFN-γ-, IL-4-, and IL-10-secreting SMNCs after the
third immunization were quantiﬁed using ELISPOT assays (Fig. 4).
Fig. 1. Experimental schedule of the NP protein. The indicated mice were immunized intramuscularly with NP protein on days 0, 14 and 28. Blood was collected from the
mice and analyzed using ELISA on days 14, 28 and 38, after which the mice were sacriﬁced, and SMNCs were separated and analyzed using the ELISPOT assay. The remaining
mice were challenged on day 38 with 20 MLD50 of inﬂuenza A virus PR8 and monitored for 3 weeks until day 59. A summary of the mouse groups is provided in the
right table.
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The results showed that NP protein alone (10 mg NP or 90 mg NP) did
not induce a cellular immune responses in mice. NP protein with
adjuvant produced a strong IFN-γ-speciﬁc cellular immune
response (Fig. 4A) and less potent IL-4- and IL-10-speciﬁc immune
responses (Fig. 4B and C). NP protein formulated with CpG
signiﬁcantly enhanced the IFN-γ-speciﬁc cellular immune responses
against NP147–155 (72756 SFC/106 SMNC) compared with NP
protein alone (G44G3, po0.01). Al(OH)3 had no clear effect on
the NP-induced IFN-γ-speciﬁc response against NP55–69 or NP147–155.
ELISPOT results also showed that the combination of Al(OH)3 plus
CpG signiﬁcantly enhanced the NP protein-induced IFN-γ-speciﬁc
response against NP55–69 (1907240 SFC/106 SMNC, G64G3,
po0.01 and G64G7, po0.01), but not against NP147–155 (42733
SFC/106 SMNC, G6EG3EG7, p40.05).
Adjuvants Al(OH)3 and CpG improved NP protein-induced cross-
protection efﬁcacy
We further investigated the effects of Al(OH)3 and CpG in
improving the cross protection induced by NP. On day 38,
immunized mice were challenged with 20 MLD50 of inﬂuenza
A/PR8. All mice immunized with normal saline (NS) (G1) or
Al(OH)3 plus CpG (adjuvant control, G2) experienced serious body
weight loss, and all died on day 10–12 after challenge (Fig. 5). Mice
immunized with NP without any adjuvant in groups 3 (G3) and 7
(G7) also showed signiﬁcant body weight loss, and some mice did
not survive the PR8 challenge. However, mice immunized with NP
formulated with CpG (G4), Al(OH)3 (G5), or Al(OH)3 plus CpG (G6)
showed less body weight loss than did G3 or G7 (G4, G5 and
G6oG3 and G7). The body weight change curve also suggested
that inclusion of CpG (G4), Al(OH)3 (G5) or Al(OH)3 plus CpG (G6)
allowed the immunized mice to recover much earlier than did
immunization with 10 mg or 90 mg NP protein (G4, G5 and G64G3
and G7) (Fig. 5A).
The survival curve showed that including CpG and Al(OH)3
adjuvants with NP protein signiﬁcantly improved the survival rate
to 27% (4/15, G4) and 47% (7/15, G5), respectively, compared with
the survival rate of 13% (2/15, G3) induced by 10 mg NP protein
alone (G44G3, pr0.05 and G54G3, pr0.01 ). Including CpG
plus Al(OH)3 improved the survival rate to 80% (12/15, G6)
(G64G3, po0.001) (Fig. 5B). A total of 43% (6/14, G7) of mice in
G7 survived lethal infection (Fig. 5B), which was similar to G5 and
signiﬁcantly lower than G6 (G7oG6, pr0.05). Analysis of the
time to death showed that mice in G3, G4, G5 and G6 suffered
death on days 8–11, 9–12, 9–11 and 10–14 after challenge,
respectively, and mice in G7 suffered death on days 10–18 after
challenge. All mice in G1 and G2 died (15/15 in G1 and G2) within
12 days after challenge (time of death: days 6–12 after challenge).
These results suggested that NP formulated with Al(OH)3 induced
a slightly higher protective immunity than did NP formulated with
CpG. However, these results were not statistically signiﬁcant
(p40.05), and NP formulated with CpG plus Al(OH)3 elicited the
highest protection among all mouse groups. Moreover, 10 mg NP
formulated with Al(OH)3 induced similar survival rates to 90 mg NP
(G5EG7, p40.05), whereas 10 mg NP formulated with Al(OH)3
plus CpG induced a higher percentage of survival than did 90 mg
NP (G64G7, po0.05).
The protection efﬁcacy induced by NP immunization was closely
associated with anti-NP humoral and cellular immune responses
To increase our understanding of the correlation between
protective effects and humoral and cellular immune responses
induced by NP immunization, correlation coefﬁcients were ana-
lyzed. The survival percentage induced by NP immunization was
strongly associated with total IgG (R¼0.754, po0.05), IgG1
(R¼0.756, po0.05), and IgG2a (R¼0.780, po0.05) isotypes of
Ab against NP protein when the humoral immune response was
considered (Fig. 6). Moreover, the survival percentage was sig-
niﬁcantly associated with the NP55–69-speciﬁc, but not with the
NP147–155-speciﬁc, cellular immune response. Particularly, the
survival percentage was strongly associated with NP55–69-speciﬁc
IFN-γ-secreting SMNCs induced by NP immunization (R¼0.872,
po0.01). These results indicate that the protective efﬁcacy of NP
protein vaccine in this study was related to both the Ab response
and the cellular immune response.
Discussion
The highly conserved internal NP of the inﬂuenza A virus is a
candidate antigen for the development of a universal inﬂuenza
vaccine. NP has been expressed in various systems, and its
immunogenicity has been tested in animal models. In our previous
study, 10 mg, 30 mg, and 90 mg NP derived from E. coli showed high
immunogenicity in BALB/c mice. A high dose of 90 mg NP induced
the highest protection among these groups (Huang et al., 2012).
The cross-protection efﬁcacy of NP has been shown in previous
reports; however, its immunogenicity requires improvement (Sipo
et al., 2011; Jamali et al., 2010; Jimenez et al., 2007). Induction of
the maximal immune response with a minimum immune dose
remains important in vaccine research. In recent studies, various
Fig. 2. NP-speciﬁc antibody titers in mice sera immunized with NP formulated with adjuvant. 5–6-week-old female BALB/c mice were vaccinated with 10 μg NP, 10 μg NP
formulated with adjuvants (CpG, Al(OH)3, Al(OH)3þCpG), or 90 μg NP on days 0, 14 and 28, as described in Fig. 1. A summary of the mouse groups is provided in the lower
table. Mice administered NS or Al(OH)3þCpG were treated as negative controls. Sera were collected from six mice in each group on days 14, 28, and 38, respectively. Serum
anti-NP IgG titers were determined using ELISA. Sera were individually tested in serial dilutions against puriﬁed NP protein. Plots show the geometric mean antibody titers,
and bars show the 95% conﬁdence interval (CI) for each treatment group. Log conversion was performed for the mice serum antibody titers before statistical analysis. Tables
above the charts show a comparison of the results. ns, not signiﬁcant; n pr0.05; nnpr0.01; nnnpr0.001 based on one-way ANOVA.
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adjuvants have been employed using genetic ligation or by
addition in the formulation to improve immunogenicity, including
nanoparticles derived from papaya mosaic virus capsid protein
(PapMV CP) (Savard et al., 2012), T-cell costimulator 4-1BBL
(Moraes et al., 2011), aluminum and monophosphoryl lipid A
(MPL) (MacLeod et al., 2013), cholera toxin B subunit (CTB) (Guo
et al., 2010), Vaxfectin (Jimenez et al., 2007), lipopolysaccharide
(LPS) (Lamere et al., 2011) and the tegument protein VP22 of
herpes simplex virus 1 (HSV-1) (Saha et al., 2006). We used CpG
and Al(OH)3 to improve the immunogenicity of the NM2e fusion
protein of the inﬂuenza virus in a previous report; the adjuvant
showed potential efﬁcacy, strengthened the immune response and
elicited cross protection after NM2e immunization in mice. A
combination of Al(OH)3 and CpG in the formulation of NM2e
induced the highest protection in mice (Wang et al., 2012). In this
study, CpG and Al(OH)3 were employed separately or in combi-
nation with 10 mg NP expressed in E. coli to improve its
Fig. 3. IgG1 and IgG2a isotypes of serum from NP-immunized mice. Mice sera on
day 38 are the same as that in Fig. 2. A summary of the mouse groups is provided in
the lower table. NP-speciﬁc IgG isotypes on day 38 were analyzed using ELISA. Plots
in A and B show the anti-NP IgG1 and IgG2a isotype titers, respectively. Scatter
plots show the results each mouse in each group, and bars show the geometric
mean for each group. Plots in C represent the anti-NP IgG1/IgG2a ratios in sera
collected from mice. Bars show the mean with SD (n¼6 mice per group, except
n¼5 in the NS- or NP-only-immunized group). Log conversion was performed for
the mouse serum antibody titers prior to statistical analysis. Lines above NP and
NPþCpG groups in A demonstrate that the two groups have similar results.
npr0.05; nnpr0.01; nnnpr0.001 based on one-way ANOVA.
Fig. 4. IFN-γ, IL-4 and IL-10 ELISPOT assays for NP-speciﬁc SMNCs were detected
using ELISPOT assays. Mice are the same as in Fig. 2. A summary of the mouse
groups is provided in the lower table. Spleen lymphocytes were separated from
mice on day 38, and 5 mg/ml of NP147–155 and NP55–69 peptides were used as stimuli
in ELISPOT assays. The numbers of SMNC-secreting IFN-γ(A), IL-4(B), or IL-10(C) in
response to 40 h stimulation with NP147–155 (left) and NP55–69 (right) peptides are
shown as SFC/106 SMNC. npr0.05; nnpr0.01; nnnpr0.001 based on one-
way ANOVA.
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immunogenicity and protective efﬁcacy. Our results demonstrated
that after the third immunization, 10 mg NP alone induced a strong
humoral immune response (anti-NP IgG titer: 4.8105) in mice,
which was markedly enhanced by the addition of CpG adjuvant
and promoted Th1 and CTL responses (Bevan, 2004). In this study,
CpG adjuvant markedly improved the anti-NP IgG2a titer, but
not IgG1 titer, thus decreasing the IgG1/IgG2a ratio. This was
suggestive of a Th1 response. Meanwhile, CpG increased the
cellular immune response against NP147–155. Inﬂuenza A virus
PR8 challenge demonstrated that including CpG in the NP for-
mulation improved the survival rate from 13% to 27%, suggesting
that the immune efﬁcacy of CpG was not sufﬁcient to completely
protect mice against the challenge. Aluminum adjuvant enhanced
the Th2 immune response (Reed et al., 2009; Tritto et al., 2009). In
the present study, Al(OH)3 increased anti-NP IgG levels by 10 fold
compared with NP protein alone (G3) and enhanced both anti-NP
IgG1 and IgG2 titers, which increased the IgG1/IgG2a ratio
compared with NP protein alone (G3 and G7). Meanwhile, includ-
ing Al(OH)3 in the NP formulation had only a minor effect on the
cellular immune response. Inﬂuenza A virus PR8 challenge showed
that including Al(OH)3 in the NP formulation improved the
survival rate to 47%, suggestive of stronger immune efﬁcacy of Al
(OH)3 than of CpG. Furthermore, Al(OH)3 and CpG showed a
synergistic effect in the NP formulation. Our results demonstrated
that a combination of Al(OH)3 and CpG increased both anti-NP
IgG1 and IgG2a titers and decreased the IgG1/IgG2a ratio com-
pared with Al(OH)3 alone. More importantly, the combination
improved the protection and resulted in the highest survival rate
of 80% among all mice groups, showing a clear synergistic effect.
An immune dose of 90 mg NP was used as a control in this study.
The high dose of 90 mg NP induced higher protection in mice than
did the low dose of 10 mg NP. Our data demonstrated that the
lower protection induced by 10 mg NP alone in mice was enhanced
by adjuvant Al(OH)3. Ultimately, including Al(OH)3 in the formula-
tion with 10 mg NP induced similar protection to 90 mg NP alone,
and including Al(OH)3 and CpG together in the formulation with
10 mg NP induced higher protection than 90 mg NP. These results
suggested that the NP subunit vaccine expressed in E. coli is
immunogenic in mice, and that the high immune dose of 90 mg
NP can be decreased to 10 mg by adding adjuvant. Adjuvant Al
(OH)3 or CpG could improve the immunogenicity and protection
efﬁcacy of NP, and a combination of Al(OH)3 and CpG in the
formulation with NP is a promising strategy for the development
of an NP-based universal inﬂuenza A virus vaccine to prevent
inﬂuenza epidemics and pandemics. Guo et al. (2010) reported
that immunization with 100 μg recombinant NP formulated with
CTB provided good cross-protection in mice, which also supports
the immunogenicity of recombinant NP derived from E. coli.
However, the dose was much higher than that used in this study.
MacLeod et al. (2013) showed that vaccination with NP formulated
with aluminum provided protection against homologous and
heterologous inﬂuenza a virus. However, when aluminum and
MPL were used together in the formulation, the combination of
NPþaluminumþMPL provided some protection against the
homologous viral strain but no protection against the heterologous
strains. Based on the above results, the addition of adjuvant
(especially for aluminum) is important for the development of a
universal inﬂuenza virus vaccine based on NP.
Understanding the immune protection mechanism of NP is
important for the development of a universal vaccine based on NP.
Once we understand the immune protection mechanism, we can
develop vaccine research strategies and improve the immunogeni-
city of the NP vaccine by applying the appropriate adjuvant or
delivery technique.
Most studies consider NP protein the primary target antigen
against CTL in inﬂuenza virus. NP elicited protective immunity
mainly through CD4þT- and CD8þT-cellular immune responses
(Lalor et al., 2008; Brewoo et al., 2013; Jimenez et al., 2007; Lo
et al., 2008; Epstein et al., 2005, 2000; Grant et al., 2013; Ulmer
et al., 1998). NP-induced CTL response may be mediated by cytokines,
secreted by Th, and implemented by Tc killing (Jameson et al., 1998,
1999). In some studies, NP vaccine-immunized T-cell-depleted mice
could not survive inﬂuenza virus challenge (Epstein et al., 2005),
Fig. 5. Comparison of NP protein and NP formulated with adjuvant providing
protection against inﬂuenza A virus PR8 challenge. Mice were immunized as
described in Fig. 1. A summary of the mouse groups and the survival rate are
provided in the lower table in this chart. Mice were challenged with 20 MLD50 of
inﬂuenza virus PR8 on day 38. Mice immunized with NS or Al(OH)3þCpG were
challenged as negative controls. Body weight loss (A) and survival (B) of the mouse
groups were monitored daily for 21 days post-challenge (n¼15 in all groups, except
n¼14 in G7). The table above graph A displays those days showing differences
among groups (po0.05); the table above graph B displays a results comparison
among these groups. ns, not signiﬁcant; npr0.05; nnpr0.01; nnnpr0.001 based
on repeated-measures ANOVA in A and log-rank (Mantel–Cox) test in B.
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whereas naïve mice could survive with adoptive transfer of T cells
from NP vaccine-immunized mice (Ulmer et al., 1998; Fu et al.,
1999). In this study, the survival percentage of mice challenged with
PR8 was strongly associated with the cellular response induced
by the NP protein. To further explore the protective mechanism
induced by NP immunization, we compared the Ab response and
cellular immune response induced by 10 mg NP formulated with Al
(OH)3 and CpG together (G6) and 90 mg NP alone (G7). Mice in G6
experienced less weight loss than those in G7. Meanwhile, challenge
results demonstrated that the survival percentage of 80% in G6 was
signiﬁcantly higher than that in G7 (43%). Immune response
analysis demonstrated that the antibody response against NP was
comparable in G6 and G7, but mice in G6 showed a higher cellular
response against NP, and those in G7 showed a lower cellular
response. Based on these results, the cellular response induced by
NP immunization improved mouse survival; however, more deﬁni-
tive results such as adoptive transfer of T cells are required to
support this hypothesis. In this study, we did not observe a
correlation between the survival percentage and the NP147–155-
speciﬁc cellular response, possibly because the NP147–155-related
response was not efﬁciently induced by the formulation in BALB/
c mice.
Although CD4þ and CD8þ T cells can be used for protection
after NP immunization, some studies have shown that T cells are
not required for protection induced by NP (Epstein et al., 2000),
which suggests that other mechanisms, such as antibodies, may
contribute to the protective effects of NP vaccine. Ab against NP
may be induced by inﬂuenza virus infection and NP vaccine
immunization (Rangel-Moreno et al., 2008); however, NP is an
internal inﬂuenza virus protein, and Ab against NP could not
neutralize virus. Further results demonstrated that adoptive
transfer of NP Ab to immune deﬁcient scid mice could not protect
the mice against inﬂuenza virus challenge. Therefore, Ab against
NP could not offer protection (Gerhard et al., 1997). In fact,
immune complexes formed by MAb against NP promoted DC
maturation, Th1-type cytokine production, and CD8þ CTL
response after inﬂuenza virus infection in normal individuals
(Zheng et al., 2007). Additionally, NP is expressed on the cell
surface of P815 infected with inﬂuenza virus NP, which can be
lysed by the complement system stimulated by NP-speciﬁc IgG
in vitro (Yewdell et al., 1981). Passive immunization of anti-NP
serum promoted clearance, decreased the severity of the disease,
and played an important role in cross protection against inﬂuenza
virus (Rangel-Moreno et al., 2008; Carragher et al., 2008; Nguyen
et al., 2007; Sealy et al., 2003). These results suggest that antibody
may be an important protective mechanism of NP (Rangel-Moreno
et al., 2008; Carragher et al., 2008). Next, Lamere et al. (2011)
demonstrated that anti-NP IgG played a protective role via a
mechanism involving both FcRs and CD8þ T cells. In this study,
NP protein expressed in E. coli induced a strong antibody response
in mice with or without adjuvant. Especially, 90 mg NP without any
adjuvant protected against inﬂuenza virus. Furthermore, correla-
tion analysis suggested that the survival percentage of mice
immunized with NP was signiﬁcantly associated with NP-speciﬁc
IgG, IgG1, and IgG2a titers.
Overall, given that both T lymphocytes and Ab against NP
contribute to cross-protection (Lamere et al., 2011; Rangel-Moreno et
al., 2008; Carragher et al., 2008), appropriate adjuvants should be used
to induce NP-related protection, similar to Al(OH)3 and CpG adjuvants.
In this study, a combination of Al(OH)3 and CpG in the NP formulation
could be used for the development of an NP-based universal inﬂuenza
A virus vaccine to prevent inﬂuenza epidemics and pandemics.
However, several issues need to be addressed, as follows:
1) The protective durability induced by NP immunization. In this
study, the immunized mice were challenged 10 days after the
last immunization. It is unknown whether they will remain
protected once the response decreases to a constant “memory”
Fig. 6. Correlation analysis between survival percentage and immune responses in mice. (A) Correlation analysis was conducted to determine the relationships between survival
percentage data from Fig. 5 and the NP-speciﬁc IgG on day 38 data (left) from Fig. 2 and IgG1 (middle) and IgG2a (right) ELISA data in Fig. 3A and B. Log conversion was performed
for the mouse serum antibody titers. (B) Correlation analysis was performed to explore relationships of the survival percentage data in Fig. 5 with the IFN-γ- (left), IL-4- (middle),
and IL-10-secreting (right) SMNCs stimulated with NP147–155 or NP55–69 peptide based on the ELISPOT data in Fig. 4. ns, not signiﬁcant; npr0.05; nnpr0.01; nnnpr0.001 based
on correlation analysis.
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level. We immunized mice with a recombinant fusion protein
of NP and M2e (NM2e) formulated with Al(OH)3 three times at
2-week intervals in a previous study. Long-term monitoring
data showed that immunization induced high levels of IgG,
which were maintained for at least 7 months, against NP and
M2e (Wang et al., 2008), Afterwards, mice immunized with
NM2eþAl(OH)3 were challenged with inﬂuenza A virus PR8
2 weeks, 2 months or 6 months after the last immunization,
respectively. Our results showed that challenge at 2 or 6 months
after the last immunization induced only a slightly lower
survival rate; however, they were not signiﬁcantly different
from the challenge results at 2 weeks after the last immuniza-
tion (data not shown). Based on these results, NPþAl
(OH)3þCpG immunization in this study may induce long-
term protection at least 6 months after the last immunization,
after which boosting immunization may be required for higher
protective efﬁcacy.
2) The practicality of a three-dose NP-based vaccine administered at
biweekly intervals. It was important to conﬁrm the immunogeni-
city of NP in this preliminary study, although the three-dose
delivery strategy was inconvenient (Savard et al., 2012; Guo et al.,
2010). The delivery strategy, such as the immunization dosage,
immunization times and delivery interval, should be optimized
for convenience. Previously, the immunization times and intervals
were evaluated using the NM2e vaccine in our lab. Mice were
immunized with NM2eþAl(OH)3 three times at 2-week intervals
or two times at 4-week intervals, respectively, and the two groups
showed comparable survival percentages (data not shown). The
two-dose immunization strategy would be preferred if the NP-
based vaccine performance is similar to that of NM2e. Further
studies are required to optimize the immunization strategy of
NPþAl(OH)3þCpG vaccine in this study.
3) Relationship between Th epitope-directed responses and Ab titers.
This study showed that NP immunization induced high levels of
antibody against NP in G3-G7; however, the Th epitope (NP55–69)-
directed response was only observed in G4, G5 and especially G6.
Thus, the Th epitope-directed response did not correlate with ELISA
titers. A helper T-cell response of NP may play a role in secreting
cytokines, such as IFN-γ and IL-2, which facilitated switching of the
immunoglobulin isotype and lysing MHC class II cells that express
the target antigens and priming of a memory CTL response in vivo
(Ulmer et al., 1998). Based on the results in G6, speciﬁc cytokines,
such as IFN-γ, but little or no IL-4 or IL-10 were secreted into the
culture supernatants of restimulated cells during NP55–69 restimu-
lation in vitro (Fig. 4), which was indicative of a Th1 type of helper
T-cell response (Ulmer et al., 1998). As may be expected from this
Th1 type of response, the immunoglobulin subtype proﬁle of anti-
NP antibodies was predominated by IgG2a, with lesser amounts of
IgG1 (Fig. 3). Notably, only one Th epitope NP55–69, but not the
entire NP protein or peptide pool of NP, was used in this study.
Moreover, ELISPOT only showed the cell spots that reacted with
speciﬁc Ab, but the magnitude of the role they play in the active,
composite response of animals remains unknown. The Th-epitope
directed response should be further characterized, such as analysis
of cytokine concentrations in the supernatant, to increase our
understanding of the Th response elicited by NP immunization.
Conclusions
NP formulated with Al(OH)3 and CpG induced optimal immune
responses and protection against the inﬂuenza A virus PR8 strain
in BALB/c mice, which indicates that a combination of Al(OH)3 and
CpG may be an efﬁcient adjuvant in the NP formulation. In
addition, the high immune dose of NP can be reduced by the use
of Al(OH)3 and CpG.
Materials and methods
Protein and peptides
The expression and puriﬁcation of NP protein in E. coli were
performed as described previously (Huang et al., 2012). Brieﬂy, the
optimized NP gene from inﬂuenza A virus A/Beijing/30/95 (H3N2)
was synthesized and ligated into the pET-30a(þ) vector (Merck-
Novagen, Darmstadt, Germany) between the NdeI and EcoRI sites
to form pET30a-NP, which was used to transform E. coli BL21(DE3)
(Merck-Novagen). The expressed NP was puriﬁed using ion-
exchange chromatography (DEAE-Sepharose Fast Flow, Amersham
Biosciences Corp., Piscataway, NJ, USA) followed by gel chromato-
graphy (Superdex 200, Amersham) with purity490%. The puriﬁed
NP was concentrated, quantiﬁed, and stored at 70 1C.
In our previous study, NP peptide pools were used to screen the
ELISPOT epitopes of NP in BALB/c (H-2d) mice infected with inﬂuenza
A virus A/PR8. We identiﬁed some ELISPOT epitopes of NP including
the CTL epitope NP147–155-(TYQRTRALV) and two potential Th epi-
topes, NP53–67-(EGRLIQNSLTIERMV) and NP57–71-(IQNSLTIERMVL-
SAF), both of which contain a portion of the H-2d restricted Th
epitope sequence NP55–69-(RLIQNSLTIERMVLS) (Wang et al., 2008).
Since NP147–155-(TYQRTRALV) and NP55–69-(RLIQNSLTIERMVLS) have
been reported in previous studies, they were used to identify the
ELISPOT response induced by the NP-based vaccine in this study.
Inﬂuenza virus
The inﬂuenza virus A/Puerto Rico/8/34 (H1N1) (A/PR8) was
inoculated into the allantoic cavity of 9-day-old chick embryos and
cultured for 2 days at 34 1C. Viral allantoic ﬂuid was then
harvested and stored at 70 1C. The MLD50 value of PR8 virus
was determined in BALB/c mice.
Immunization and virus challenge
5–6-week-old SPF female BALB/c mice were obtained from the
Institute of Experimental Animals, Chinese Academy of Medical
Sciences, and raised in an animal house in the Institute for Occupa-
tional Health and Poison Control (IOHPC), Chinese Center for Disease
Control and Prevention (China CDC). This mouse study was conducted
in strict accordance with the recommendations of the Guide for the
Care and Use of Laboratory Animals of China CDC. The protocol was
approved by the Committee on the Ethics of Animal Experiments of
IOHPC (Permit number: EAWE-2010-029). Aluminum hydroxide gel
(Alhydrogel, Brenntag Biosector, DK-3600 Frederikssund, Denmark) (Al
(OH)3) and CpG 1826 (50-TCCATGACGTTCCTGACGTT-30) (synthesized
in Takara Biotechnology (Dalian) Co., Ltd., Japan) were used as
adjuvants, separately or in combination, with NP protein. The mice
were injected intramuscularly with NP protein alone or with adjuvant
(Table 1). Mice immunized with placebo normal saline (NS) or Al(OH)3
plus CpG were used as controls. Immunization was performed three
times at 2-week intervals (Fig. 1). Blood samples were collected from
six mice in each group on days 14, 28 and 38, after which mice were
sacriﬁced, and spleens were aseptically removed and ground through
a 200-mesh sieve. Spleen mononuclear cells (SMNCs) were obtained
after erythrocytes were depleted using Ammonium-Chloride–Potas-
sium (ACK) lysis buffer (0.15 mol/L NH4Cl, 0.01 mol/L KHCO3 and
0.1 mol/L Na2-EDTA.2H2O, pH 7.2–7.4). On day 10 after the ﬁnal
immunization, 15 mice in each group were anesthetized with sodium
pentobarbital (10 mg/ml) at a dose of 60 mg/kg body weight and
challenged with 50 ml of 20-MLD50 PR8 by intranasal infection. The
daily body weight loss andmortality were monitored for 3 weeks after
challenge. Mice that lost 30% of their initial weight were euthanized
and scored as dead (Wang et al., 2014; Tompkins et al., 2007; Patterson
et al., 2007). All experiments were performed twice.
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ELISA protocol
NP protein-speciﬁc antibody titers were measured using ELISA.
The 96-well ELISA plates were pre-coated with 100 μl of NP protein
(2 μg/ml) in 50 mM sodium bicarbonate buffer (pH 9.6) overnight at
4 1C. Washed wells were blocked by incubation with PBS containing
2% BSA (Amresco, Solon, OH, USA) for 2 h at 37 1C. A total of 100 ml
of serially diluted serum samples in PBS containing 1% BSA were
added to each well and incubated for 1.5 h at 37 1C, followed by the
addition of 100 μl of horseradish peroxidase-conjugated goat anti-
mouse IgG (1:10,000 dilution) (Sigma-Aldrich, St. Louis, MO, USA),
IgG1 or IgG2a (Southern Biotech, Birmingham, AL, USA) (1:5000
dilution), respectively, for 1.5 h at 37 1C. After washing, 100 μl of
tetramethylbenzidine (TMB) substrate was added to each well.
Plates were incubated for 5 min at room temperature in darkness.
The reaction was stopped by adding 50 ml of 1 M H2SO4. The
absorbance at 450 nm was determined using an ELISA reader
(Thermo Labsystems Dragon, Wellscan MK3, Thermo Fisher
Scientiﬁc, Inc., Waltham, MA, USA). Antibody levels in serum were
expressed as endpoint titers and deﬁned as the highest sample
dilution with an OD 450 nm reading greater than 2.1-fold the mean
value of the naïve samples (unvaccinated mice serum).
ELISPOT assay
The number of peptide NP55–69-(RLIQNSLTIERMVLS, Th epitope
in BALB/c (H-2d) mice) and NP147–155-(TYQRTRALV, CTL epitope in
BALB/c (H-2d) mice) speciﬁc SMNCs that secreted IFN-γ, IL-4, or
IL-10 from immunized mice was determined using the murine
ELISPOT kit (BD Biosciences, Franklin Lakes, NJ, USA) according to
the manufacturer's instructions. Brieﬂy, ELISPOT plates were
coated with anti-murine IFN-γ, IL-4, and IL-10 antibodies (5 mg/
ml) overnight at 4 1C. RPMI-1640 medium containing 10% fetal
bovine serum (FBS, GIBCO, Langley, OK, USA) (R-10) was added to
block nonspeciﬁc sites for 2 h at room temperature. SMNCs were
aseptically isolated, and 5105 SMNCs suspended in 100 μl of
R-10 containing 10 mg/ml of NP55–69 or NP147–155 were added to
each well. After incubation for 40 h in a 5% CO2 incubator at 37 1C,
100 ml detection antibody (biotinylated anti-mouse IFN-γ, IL-4, or
IL-10; 2 mg/ml) was added to each well and incubated for 2 h at
room temperature. Then, 100 ml enzyme complex solution (100-
fold dilution) was added, followed by incubation for 1 h at room
temperature. Substrate solution (100 ml) was added to each well,
and the reaction was allowed to proceed for 20 min at room
temperature in darkness. The ELISPOT plate was rinsed with ﬂowing
water to terminate the reaction. An ELISPOT image analyzer
(Bio-SYS GmbH, Bioreader 4000 PRO-X, Karben, Germany) was
used to determine the number of spot-forming cells (SFCs).
Statistical analysis
SPSS (version 17.0) and Prism (version 5.0a) softwares were
used for statistical analysis. Antibody titers were converted by
log10 before statistical analysis. Statistical analysis of the antibody
titers and ELISPOT results among groups was performed using
one-way ANOVA. The weight changes on each day were analyzed
using repeated-measures ANOVA. Survival-rate curves were ana-
lyzed using the Log-rank (MantelCox) test. Differences with
pr0.05 were considered signiﬁcant.
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